Anti-Osteoporosis And Fracture Healing Market 2026: Upcoming Trends, Growth Drivers, Opportunities and Challenges By Top Players Like Radius Health, Pfizer, Amgen, Novartis AG, GlaxoSmithKline Plc.

Anti-Osteoporosis and Fracture Healing Market Regional Analysis
North America anti-osteoporosis and fracture healing market is expected to witness significant growth over the forecast period owing to new product launches. For instance, in September 2018, Zydus Pharma Inc. received approval from U.S. Food and Drug Administration (FDA) for launch of Risedronate Sodium delayed release tablets in America, a drug used for osteoporosis treatment in postmenopausal women.

Anti-Osteoporosis and Fracture Healing Market Key Players
Some of the key players operating in the anti-osteoporosis and fracture healing market are Radius Health Inc., Pfizer Inc., Amgen Inc., Novartis AG, GlaxoSmithKline Plc., Merck & Co., Inc., F. Hoffman-La Roche AG, Eli, Lilly and Company Limited, and PhytoHealth Corporation.

Request For A Sample Copy Of This Research Report: www.coherentmarketinsights.com/insight/request-sample/2525

Osteoporosis involves a condition, which results when the rate of bone tissue regeneration is much less than its breakdown, making the bones porous. Osteoporosis is more prevalent in female, where more cases occur after menopause due to decrease in estrogen hormone levels. In osteoporosis, the strength and structure of bones is affected, which increases the probability of occurrence of fractures, especially in hip region, wrists, and spine. An X-ray based scanning method, Dual Energy X-ray Absorptiometry (DEXA) or bone densitometry, is used for diagnosis of the condition. Osteoporosis has no clear symptoms, although is characterized by spine weakening and joint pain.

Anti-Osteoporosis and Fracture Healing Market Drivers
In the recent past, various regulatory bodies such as European Medicines Agency (EMA), U.S. Food and Drug Administration (FDA), Medicines and Healthcare Products Regulatory Agency (MHRA), and others approved new drugs for treatment of osteoporosis. Approval and launch of such new drugs are expected to drive global Anti-Osteoporosis and Fracture Healing Market growth over the forecast period. For instance, in April 2017, Radius Health Inc., a biopharmaceutical company, received approval from U.S. Food and Drug Administration (FDA) for TYMLOS (abaloparatide) injection, for treating postmenopausal women with osteoporosis who are at high risk of fracture. This drug reduces the occurrence of spinal cord and peripheral skeleton fractures in postmenopausal women.

In April 2018 Amgen Inc., an American biopharmaceutical company, received approval from Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for marketing of Prolia (denosumab) in Europe. Denosumab is used for treating bone loss associated with prolonged systemic glucocorticoid therapy in patients who are at increased risk of fracture. This is expected to drive the Europe anti-osteoporosis and fracture healing market growth over the forecast period.

Download The PDF Brochure: www.coherentmarketinsights.com/insight/request-pdf/2525

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

This release was published on openPR.